
Yatharth Hospital & Trauma Care Services Q1 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- Expect revenue close to INR 1000 crores this year, driven by growth across facilities (Page 17).
- Inpatient volume grew 28% YoY to 15,235 this quarter, with notable growth in Noida Extension (81% revenue increase, 38% contribution) (Pages 5, 9).
- ARPOB (Average Revenue Per Occupied Bed) is improving, reaching INR 30,551 in Q1; expected to increase further with improved case mix and pricing (Pages 5, 17).
- Capacity expansion underway: 200 beds in Greater Noida and 250 beds in Noida Extension planned within 2-2.5 years, expected to achieve over 50% utilization within two years post-expansion (Pages 11, 17).
- Addition of 3,000 beds targeted by FY 2028 via brownfield expansions, acquisitions, and O&M models, primarily in North India, Delhi NCR, UP, and Rajasthan (Pages 7, 11-12).
- Faridabad hospital occupancy to grow from current 10% to 30% by year-end, contributing to revenues (Page 10).
- Oncology and super-specialty services expected to increase contribution and ARPOB, supporting volume growth (Pages 5, 9).
See what Yatharth Hospital & Trauma Care Services management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- The company currently has cash of INR 1,826 million and has reduced finance costs after IPO, improving capital efficiency.
- Future expansions, including adding roughly 450 beds at Greater Noida and Noida Extension in 2-2.5 years, are expected to be funded largely through internal accruals.
- There is scope for taking on additional debt if required, though efforts are made to utilize internal accruals and existing cash.
- The company is also exploring acquisition opportunities, including operational and management (O&M) models, which require less capital outlay.
- Overall, the financing strategy for growth includes a mix of internal accruals, available cash, and selective debt, with no specific mention of planned equity fundraising in the near term.
See what Yatharth Hospital & Trauma Care Services management said on order book — free account, 30 seconds.
Capex plans
Yes- Brownfield expansions at Noida Extension and Greater Noida hospitals: adding 250 beds at Noida Extension and 200 beds at Greater Noida, expected in 2-2.5 years, with capex around INR 65 lakh per bed funded through internal accruals.
- Capex increased by INR 60 crores this quarter primarily due to medical equipment including robotics and advanced surgical tools for neurosurgery and cardiac surgeries.
- Strategic investments in robotics and super-specialty services, including oncology and organ transplant programs.
- Plans for further bed capacity expansion aiming to reach 2,800 to 3,000 beds by FY '28 through a mix of internal accruals, debt, and O&M model acquisitions to limit asset-heavy outflows.
- Ongoing efforts to acquire new hospitals, with recent acquisitions in Jhansi-Orchha and Faridabad, and active discussions for two more hospitals in Delhi NCR and Uttar Pradesh.
- Signing NDA with major audit firms for process strengthening, indicating strategic governance investments.
Track Yatharth Hospital & Trauma Care Services — get its next earnings analysis in your feed
How does Yatharth Hospital & Trauma Care Services rank vs peers in Healthcare Services?
Pro featureHow does Yatharth Hospital & Trauma Care Services rank in Healthcare Services?
Compare Yatharth Hospital & Trauma Care Services against every Healthcare Services company (Q1 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Yatharth Hospital & Trauma Care Services's management said in earlier quarters
Others in Healthcare Services this season
- Chandan Healthca (Q2 FY27)
Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor
- Invicta Diagnostic (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2
- Unihealth Hosp (Q2 FY27)
1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r
- Sangani Hospital (Q2 FY27)
1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.